The 36-month beta value for BCAB is also noteworthy at 0.92. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BCAB is 44.57M, and at present, short sellers hold a 9.51% of that float. The average trading volume of BCAB on June 13, 2025 was 546.34K shares.
BCAB) stock’s latest price update
BioAtla Inc (NASDAQ: BCAB) has experienced a decline in its stock price by -7.41 compared to its previous closing price of 0.46. However, the company has seen a fall of -6.22% in its stock price over the last five trading days. globenewswire.com reported 2025-06-02 that 45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an ORR of 3.4% Plan to finalize Phase 3 trial design in 2L+ HPV+ OPSCC with the U.S. Food and Drug Administration (FDA) SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck.” The poster will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois.
BCAB’s Market Performance
BioAtla Inc (BCAB) has experienced a -6.22% fall in stock performance for the past week, with a -2.57% drop in the past month, and a 32.11% rise in the past quarter. The volatility ratio for the week is 5.63%, and the volatility levels for the past 30 days are at 7.01% for BCAB. The simple moving average for the past 20 days is -1.59% for BCAB’s stock, with a -56.63% simple moving average for the past 200 days.
Analysts’ Opinion of BCAB
JMP Securities, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $17. The rating they have provided for BCAB stocks is “Mkt Outperform” according to the report published on September 15th, 2022.
Credit Suisse gave a rating of “Neutral” to BCAB, setting the target price at $5 in the report published on May 05th of the previous year.
BCAB Trading at 4.85% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.04% of loss for the given period.
Stock Fundamentals for BCAB
Current profitability levels for the company are sitting at:
- -6.1 for the present operating margin
- 0.98 for the gross margin
The net margin for BioAtla Inc stands at -5.63. The total capital return value is set at -3.01. Equity return is now at value -246.21, with -97.07 for asset returns.
Based on BioAtla Inc (BCAB), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -103.6.
Currently, EBITDA for the company is -73.94 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of -0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In summary, BioAtla Inc (BCAB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
